HOME
PRODUCT
SOLUTION
SUPPORT
SHOP
ABOUT
CONTACT
2024.05
Celnovte self-cloned primary antibodies won optimal in NordiQC assessment.
2024.10
2025.03
Celnovte PR NordiQC Assessment, Class III NMPA certificate
2025.04
Celnovte self-cloned primary antibodies won optimal in NordiQC assessment for 6 consecutive years.
Celnovte HER2 NordiQC Assessment & Class III NMPA certificate
2025.05
Download Celnovte CDX2 NordiQC Assessment Documentation
2021.05
Download Celnovte CD56 NordiQC Assessment Documentation
Download Celnovte CD15 NordiQC Assessment Documentation